Mesalamine delayed-release tablets have an outer protective coat consisting of a combination of acrylic
In 2% to 3% of patients in clinical studies, intact or partially intact tablets have been reported in Descriptions
Multiple mesalamine formulations are available, with similar safety and efficacy profiles
3% after 2 hours in gastric pH, 0
Up to 74% of patients with mild to moderately active ulcerative colitis experience endoscopic or symptomatic improvement (including remission) or both when treated with oral delayed-release mesalazine 2
Mesalamine also has the chemical name 5-amino-2-hydroxybenzoic acid and its structural formula is: COOH
4 grams/day based on body weight strata of 17 to less than 33 kg, 33 to less than 54 kg
8 g daily
09% after 2 h In contrast to these 3 formulations, Asacol is a delayed-release formulation that releases mesalamine in the terminal ileum and right colon; however, clinical trials clearly have shown that it is effective in patients regardless of anatomic extent of UC (proctitis, left-sided disease, and pancolitis)
A07EC02
PENTASA (mesalamine) for oral administration is a controlled-release formulation of mesalamine, an aminosalicylate anti-inflammatory agent for gastrointestinal use
OH